Background/Aim: Presently, there are no therapeutic options for unresectable hepa-
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| INTRODUCTION
For treatment of unresectable hepatocellular carcinoma (u-HCC), tyrosine kinase inhibitors (TKIs), such as sorafenib (SOR) 1, 2 and regorafenib (REG), 3, 4 have been introduced.
SOR was developed as a first-line agent for u-HCC, while REG is used as second-line therapy in patients who show good tolerability and progressive disease (PD) with SOR. Recently, lenvatinib (LEN), a new TKI, 5, 6 has become available as a first-line drug for u-HCC. However, though the number of TKIs for u-HCC has increased, there is presently no therapeutic option for patients with SOR failure or who show intolerability for SOR as well as failure with REG, indicating an important and practical unmet need. Following the introduction of LEN in clinical practice in Japan in March 2018, the drug has been used in real-world practice not only for TKI-naïve but also for TKI-experienced patients as second-or third-line treatment. 7 On the other hand, therapeutic response and adverse events (AEs) associated with LEN treatment for u-HCC patients with and without a past history of TKI have not been elucidated. In the present study, we analyzed clinical features of patients who received LEN treatment for u-HCC for therapeutic response and AEs.
| MATERIALS AND METHODS
From March to August 2018, LEN (Lenvima ® , Eisai Co., Ltd., Tokyo, Japan) was given to 105 u-HCC Japanese patients receiving treatment at 13 Red Cross Hospital n = 3]). We retrospectively examined the records of those patients and collected clinical data obtained at the introduction of LEN, as well as after 2 weeks and every 4 weeks thereafter. Following exclusion of those who started with a reduced LEN dose and/or had a short observation period (<2 weeks), 77 patients were enrolled and divided into two groups, TKI naïve (n = 33) and TKI experienced (n = 44), according to their past history with TKI treatments. Flow diagram of enrolled patients is shown in Figure 1 . 
| LEN treatment and assessment of AEs
After obtaining written informed consent, LEN was orally administered at 8 mg/d to patients weighing <60 kg and 12 mg/d to those ≥60 kg, and discontinued when any unacceptable or serious AE or clinical tumor progression was observed. According to the guidelines for administration of LEN, the drug dose should be reduced or treatment interrupted when a patient develops any grade 3 or more severe AE or if any unacceptable grade 2 drug-related AE occurs. AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. 21 The worst grade for each AE during the present observation period was recorded. If a drug-related AE occurred, dose reduction or temporary interruption was maintained until the symptom was resolved to grade 1 or 2, according to the guidelines provided by the manufacturer. 
| Evaluation of therapeutic response

| RESULTS
Following exclusion of patients whose initial LEN dose was reduced or those with a short observation period <2 weeks, a total of 77 were analyzed and their characteristics are shown in (Figure 2A ), while OSR was 98.6%, 96.9%, and 93.4%, respectively ( Figure 2B ). Although older age, shorter observation period, lower frequency of past history of hypertension, and reduced tumor burden shown by lower TNM stage with both systems were noted in the TKInaïve group as compared to the experienced group, there were no significant differences between them in regard to clinical characteristics, especially hepatic reserve function (ChildPugh score, ALBI score/grade, mALBI grade) ( Table 1) . As a result, PFSR and OSR at 4, 8, and 12 weeks were not significantly different between the TKI-naïve and TKI-experienced groups (PFSR: naïve group, 89.7%, 80.4%, 80.4% vs experienced group, 90.5%, 83.0%, 80.1%, respectively, P = 0.499; OSR: 96.7%, 96.7%, 96.7% vs 100%, 97.4%, 92.3%, respectively, P = 0.769) ( Figure 3A,B) . A significant decline in log10 AFP from the baseline to 4 weeks after introducing LEN was observed in all patients who obtained disease control (PR:SD = 20:22) (baseline vs 4 weeks: 2.047 ± 1.148 vs 1.796 ± 1.179, P < 0.001). After exclusion of those with normal AFP level (<10 ng/mL) (n = 13), the significant relative decline remained (baseline vs 4 weeks: 2.662 ± 0.798 vs 2.393 ± 0.946, P = 0.002) (n = 29).
After starting LEN treatment, patients with Child-Pugh class A had worsened to Child-Pugh B or C in 23.4% of patients at 4 (P < 0.001) and in 23.7% at 12 weeks (P = 0.002) (Figure 4 ). Furthermore, a significant decline in ALBI score from the baseline (−2.32 ± 0.49) was observed at 4 (−2.18 ± 0.54 [n = 67], P < 0.001) and 12 (−2.10 ± 0.55 [n = 43], P < 0.001) weeks after the start of LEN treatment. AEs that occurred following the start of LEN in these patients are presented in Table 2 . HFSR was the most common in the present cohort (all grades: n = 31 [ an AE during the present observation period, LEN was abandoned in 17 (PD, n = 5; AEs, n = 12). The median period to initial dose reduction or pause of LEN was 40 days. Of 8 with an HFSR with a grade of 3 in previous treatments with a TKI, 87.5% also had an HFSR (grade 3, 2, 1; n = 2, 3, 2, respectively) with LEN treatment, while 44.4% of 18 with an HFSR with a grade of 2 during previous TKI treatments had an HFSR with LEN (grade 3, 2, 1; n = 3, 3, 2, respectively) ( Figure 5 ). The data of CT imaging findings at introducing LEN were obtained for 51 patients, of whom 18 (35.3%) had MVL. As a sub-analysis, relative changes in muscle volume at 4 and 12 weeks after introducing LEN were evaluated in 41 and 25 patients, respectively, whose data of CT imaging findings obtained at the start of and approximately 4 and 12 weeks after beginning treatment. In those, the relative change in PI with total psoas muscle area at L3 level in the 41 patients after 4 weeks was −0.210 ± 0.315 cm 
| DISCUSSION
Development of TKI treatment for u-HCC has improved the prognosis of affected patients. Following the introduction of SOR, global trials of sunitinib, 26 brivanib, 27 linifanib, 28 and erlotinib plus SOR 29 were conducted, though none of those drugs showed superiority and each of the trials ended in failure. Thus, there was no additional first-or second-line TKI treatment for u-HCC developed until the introductions of REG 3,4 and LEN. 6 Recently, REG was developed as a second-line option for SOR in patients who met the RESORCE trial criteria, 3 after which LEN became available as a firstline oral TKI targeting VEGF receptors 1-4, PDGF receptor α, RET, and KIT. 6 In the present study, early therapeutic response with LEN was favorable and patients obtained disease control within 4 weeks, as follow-up imaging showed a significant decline in log10 AFP from the baseline. Kuzuya et al 30 have reported that a decreased AFP ratio from the baseline at 4 weeks after introduction of SOR was a predictor of good therapeutic response (PR, SD). Thus, a decline of log10 AFP from the baseline within the first 4 weeks might also have predictive value for therapeutic response in patients receiving LEN treatment. In addition, a previous study noted that fever within 2 weeks after the start of SOR therapy may be useful as a predictor of favorable treatment response in patients with advanced HCC and receiving SOR treatment. 31 Three of our patients developed a fever within 2 weeks after the start of LEN (grade 1, 2, 3: each 1 patient), in whom therapeutic response was PD in 2 and SD in 1. It would be important to examine the clinical importance of fever in patients receiving LEN therapy as a useful predictor of a favorable treatment response in a future study with a larger number of patients. Not all patients treated with SOR in clinical practice meet the RESORCE trial criteria; thus, the frequency of u-HCC patients indicated for REG has been reported to only range from 30.6% to 37.0% of those confirmed by radiological In the present cohort, Child-Pugh class and ALBI score became worse at 4 and 12 weeks after starting LEN treatment. In addition to HFSR, general fatigue and appetite loss were the second and third most frequent AEs seen in the present analysis, and it is thought that LEN and these AEs have direct effects on liver function and nutritional status. To maintain adherence to LEN therapy, it is important not only to monitor and treat as carefully as possible AEs but also to keep in mind to introduce LEN, as well as SOR, as possible as in better liver function, if necessary for LEN treatment.
HCC is often seen in patients with chronic liver disease (CLD). Additionally, MVL is not rare in affected patients 14 and its frequency was shown to increase in association with the progression of CLD stage. 38 Moreover, it has been reported that MVL is a more significant prognostic factor than portal hypertension in liver cirrhosis (LC) patients (Child-Pugh class A/B), 39 and also an important prognostic factor following not only surgical resection 40 but also SOR treatment 41 in patients with HCC. Recently, a metaanalysis study reported that MVL was a prognostic factor regardless of therapeutic modality given for HCC by Chang et al. 42 Furthermore, in addition to LC and HCC, muscle volume has been reported to be an important prognostic factor in patients receiving treatments for other types of F I G U R E 5 Hand-foot skin reaction occurrence in tyrosine kinase inhibitor-experienced group. Of 8 patients who had undergone past tyrosine kinase inhibitor (TKI) treatments and developed a grade 3 hand-foot skin reaction (HFSR), 87.5% had an HFSR with lenvatinib (LEN) therapy (G3, 2, 1; n = 2, 3, 2, respectively). Furthermore of 18 with a grade 2 HFSR in past TKI treatments, 44.4% had an HFSR with LEN (G3, 2, 1; n = 3, 3, 2, respectively). Of 4 with a grade 1 HFSR in previous TKI treatments, grade 2 occurred in 1 and no HFSR was seen in 3 with LEN treatment. In 14 without an HFSR in past TKI treatments, 28.6% developed HFSR with LEN treatment (G3, 2, 1; n = 3, 3, 2, respectively)
cancers. 43 In the present study, a fair percentage of our patients (35.3%) had MVL and a relative decline in muscle volume at 4 and 12 weeks after starting LEN was observed in patients who had data of CT imaging findings available, similar to our past study of patients treated with SOR. 41 It will be important to analyze the relationships among therapeutic response, OSR, and muscle volume in patients undergoing LEN therapy in a future study. Although some trials of intervention with nutrition and exercise CLD patients have been reported, 44, 45 effective intervention meth-
ods have yet to be reported. Establishment of strategies for preventing and improving muscle wasting in CLD patients with and without HCC is needed for improving prognosis. The present study has some limitations, including its retrospective nature. Additionally, though this was a multicenter study, the number of analyzed patients was not large and the observation period was limited. In a future study, we hope to examine the relationship between prognosis and clinical features including AEs and muscle volume with a larger number of patients receiving LEN therapy.
In summary, regardless of previous TKI treatments, therapeutic response and AE occurrence following introduction of LEN treatments were similar. We consider that LEN might complement the unmet need for TKI therapy for patients with u-HCC.
